Cerulean Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the design and development of nanopharmaceuticals. Cerulean’s nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance efficacy and tolerability of therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules.

Cerulean is pursuing three key strategies:

• Achieving rapid and clinically significant human proof of concept with its technology.
• Building a deep and diversified product pipeline and leveraging its proprietary nanotechnology platform.
• Using a multi-faceted business model, with plans to retain some products for development and commercialization to achieve full company value creation, while at the same time collaborating on other products to leverage the resources and capabilities of partners.

Cerulean has assembled a world-class management team, board of directors, and scientific advisory board that collectively have a significant track record of business building, product development, and scientific breakthroughs.

Cerulean was founded in October of 2006 and is located in Cambridge, Massachusetts.